Related Experiment Video
Updated: Aug 13, 2026

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
Published on: February 17, 2017
Heparin/low molecular weight heparin and tissue factor pathway inhibitor
1Department of Medicine, Aker University Hospital, Oslo, Norway.
Abstract:
Tissue factor pathway inhibitor (TFPI) is the factor Xa (FXa)-dependent coagulation inhibitor. TFPI is released to the blood after injection of heparin or low molecular weight heparin (LMWH). The post-heparin anticoagulant effect is caused by this release of TFPI. Free TFPI has higher affinity for heparin than TFPI which is associated with lipoproteins. Heparin increases the rate of inactivation of FXa and of tissue factor-F VIIa by TFPI. Immunoblocking of TFPI reduces the anticoagulant effect of heparin in blood activated by tissue factor considerably. Both antithrombin and TFPI participate in the anticoagulant effect induced by heparinization of blood or plasma.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

